| Identification | Back Directory | [Name]
N-{3-[(diphenylacetyl)amino]propyl}-4-oxo-3,4-dihydro-2-quinazolinecarboxamide | [CAS]
1119503-63-7 | [Synonyms]
JNc-440
(JNc440)
N-{3-[(diphenylacetyl)amino]propyl}-4-oxo-3,4-dihydro-2-quinazolinecarboxamide | [Molecular Formula]
C26H24N4O3 | [MOL File]
1119503-63-7.mol | [Molecular Weight]
440.49 |
| Hazard Information | Back Directory | [Uses]
JNc-440 is a potent antihypertensive agent. JNc-440 can enhance the interaction of TRPV4 and Ca2+-activated potassium channel 3 (KCa2.3) in endothelial cells. JNc-440 can also enhance vasodilation, and exerted antihypertensive effects in mice[1]. | [Biological Activity]
JNc-440 is a potent antihypertensive agent. JNc-440 can enhance the interaction of TRPV4 and Ca2+-activated potassium channel 3 (KCa2.3) in endothelial cells. JNc-440 can also enhance vasodilation, and exerted antihypertensive effects in mice[1].
JNc-440 (1 mg/kg; IV; single dosage) improves endothelium-dependent relaxation in small resistance arteries and to lower blood pressure[1]. | [in vivo]
JNc-440 (1 mg/kg; IV; single dosage) improves endothelium-dependent relaxation in small resistance arteries and to lower blood pressure[1]. | Animal Model: | TRPV4-/- and wild‐type C57BL/6J mice (hypertensive induced by NOS inhibitor Nω-nitro-L-arginine, AngII and high-salt diet)[1] | | Dosage: | 1 mg/kg | | Administration: | IV; single dosage | | Result: | Increased the impaired TRPV4‐KCa2.3 interaction to improve endothelium‐dependent relaxation in small resistance arteries and to lower blood pressure. |
| [storage]
Store at -20°C | [References]
[1]. He D, et al. Treatment of hypertension by increasing impaired endothelial TRPV4-KCa2.3 interaction. EMBO Mol Med. 2017 Nov;9(11):1491-1503. |
|
| Company Name: |
PHARMEKS Ltd.
|
| Tel: |
+7 (495) 702-9648 |
| Website: |
www.pharmeks.com |
| Company Name: |
Specs
|
| Tel: |
+31 15 251 8111 |
| Website: |
www.specs.net |
|